Nurix Therapeutics Inc
For the period ended Nov 30, 2023. Filed Feb 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 15, 2024
NRIX$16.14+5.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(in thousands, except share and per share amounts)
| Year Ended November 30, | ||
|---|---|---|
| 2023 | 2022 | |
| Revenue: | ||
| Collaboration revenue | $56,987 | $38,627 |
| License revenue | 20,000 | — |
| Total revenue | 76,987 | 38,627 |
| Operating expenses: | ||
| Research and development | 189,148 | 184,497 |
| General and administrative | 42,902 | 37,997 |
| Total operating expenses | 232,050 | 222,494 |
| Loss from operations | (155,063) | (183,867) |
| Interest and other income, net | 11,115 | 3,507 |
| Net loss | $(143,948) | $(180,360) |
| Net loss per share, basic and diluted | $(2.65) | $(3.71) |
| Weighted-average number of shares outstanding, basic and diluted | 54,337,901 | 48,607,990 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.